Table 2 Improvements in AEOL-10150 in terms of use as an anti-chemical warfare agent released by Aeolus Pharmaceuticals
From: Improvements in SOD mimic AEOL-10150, a potent broad-spectrum antioxidant
Time (M/D/Y) | Contents |
|---|---|
11/07/2007 | AEOL-10150 protects SM-induced lung damage |
04/23/2008 | AEOL-10150 significantly protects against SM-exposure-induced lung and skin damage |
02/09/2009 | NIH Counter ACT program begins assessing treatment with Aeolus pharmaceuticals’ AEOL-10150 against SM gas damage |
10/07/2009 | AEOL-10150 protects lungs against SM damage in animal research |
11/04/2009 | AEOL-10150 protects lungs against Cl2 exposure in animal research |
06/29/2010 | AEOL-10150 significantly protects skin in preclinical SM damage studies |
06/30/2010 | AEOL-10150 protects lungs against SM exposure in animal research |
10/10/2011 | NIH grant of $12.7 million awarded to continue development of AEOL-10150 as a countermeasure to Cl2 and SM damage |
10/24/2011 | Aeolus pharmaceuticals announces NIH award to develop AEOL-10150 as a countermeasure to nerve agent exposure |
07/30/2012 | AEOL-10150 announced to eliminate oxidative stress and nerve damage following exposure to nerve agent |
06/26/2013 | AEOL-10150 significantly ameliorates survival in animals exposed to SM |
07/02/2013 | AEOL-10150 significantly ameliorates survival from nitrogen mustard exposure to skin in animals |
09/11/2013 | AEOL-10150 is the subject of a $4.3 million US government award defining countermeasures to nerve agents; data show that the drug significantly ameliorates survival in animals following exposure to pilocarpine, a nerve agent surrogate for soman and sarin gas |
06/18/2014 | Aeolus proclaims the publication of data demonstrating the efficacy of AEOL-10150 in an animal CEES model of SM skin damage |
07/01/2014 | Aeolus proclaims additional data demonstrating efficacy of AEOL-10150 as a medical treatment against exposure to nerve agents, SM and nitrogen mustard gas |
03/31/2015 | Aeolus receives a notice of allowance from the Israeli patent office for the use of AEOL-10150 and other Aeolus compounds to treat damage from exposure to SM |
09/06/2016 | Aeolus proclaims positive data demonstrating the efficacy of AEOL-10150 as a medical treatment against SM |
09/19/2016 | Aeolus proclaims publication of additional data showing the efficacy of AEOL-10150 in SM exposure in the journal Toxicological Sciences |